Eli Lilly’s oral glucagon-like peptide-1 receptor agonist (GLP-1RA) has shown success again in two more Phase III trials in patients with type 2 diabetes. In the ACHIEVE-2 (NCT06192108) orforglipron ...

The Christian Health Association of Ghana (CHAG) has presented 20 desktop computers to selected facilities to enhance ...

The Aging and Disability Resource Center (ADRC) is offering a program called ‘Healthy Living with Diabetes,' and the last day ...

Californians will be able to buy five packs of insulin pens for a maximum of $55 per pack, or $11 per pen, starting Jan. 1, ...

New research shows that substantially more Americans would qualify as being obese using new diagnostic criteria released this ...

California will become the first state to sell its own affordable insulin next year, with CalRx biosimilar insulin pens set ...

Petaluma police are warning of road closures and possible traffic delays Friday near Lagunitas Brewing Company as locals make ...

Californians will be able to buy five packs of insulin pens for a maximum of $55 per pack, or $11 per pen, starting Jan. 1, ...

Drugs targeting the glucagon-like peptide 1 receptor (GLP-1R) offer several positive effects for individuals with type 2 ...

Lawmakers have focused on the high cost of diabetes drugs. The announcement will make state-branded insulin available two ...

Explore the latest insights on canine diabetes management, treatment options, and innovative continuous monitoring techniques in veterinary care.

Key Points Chesapeake sold 9,875 Eli Lilly and Company shares; estimated trade value of approximately $7.68 million, based on the average price for Q2 2025 Transaction represented 6.9% of fund AUM.